Metabolomics Analysis of Functional Activity Changes in Residual Tumour Cells After IOCS Treatment
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Lai-Wei You und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Ningxia Medical University, Ningxia, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Metabolomics, Neoplasm, Residual. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pudong New Area Science & Technology Development Fund (PKJ2022-Y27), Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2022-5), National Natural Science Foundation of China (No: 82170225).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a serious and often lethal cancer, particularly in patients with chronic liver disease. Currently, no specific treatment has been utilised to prevent HCC. The detailed mechanism of HCC is still elusive, and this study aims to identify and characterise the functional activity changes in residual tumour cells following intraoperative cell salvage (IOCS) treatment during HCC surgery. This research is a retrospective case–control study, involving the selection of 60 patients with HCC who underwent radical surgery; then blood and tumour tissue were collected for further testing. GC–MS assay, immunofluorescence, Western blot and qRT‐PCR techniques were employed. Our study found comparable demographic and baseline clinical characteristics between the experimental group ( n = 30), which received IOCS treatment during surgery, and the control group ( n = 30), which did not receive IOCS treatment, validating subsequent analyses. Metabolomic analysis revealed six key metabolites differing between groups, indicating improvement in liver tumours in the experimental group. TP53 expression was significantly upregulated, potentially mediating therapeutic effects. The intervention reduced HCC cell migration and apoptosis, decreased E2F1 and MDM2 protein and mRNA levels, and increased TP53 and CTNNB1 levels. These findings support the potential clinical application of the intervention in improving treatment outcomes for HCC patients, warranting further investigation to elucidate the underlying mechanisms and optimise therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Ningxia Medical University, Ningxia, China.
- Postgraduate Training Base in Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, China.
- Department of Anesthesiology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
- Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
ORCID-Profile: Jianrong Guo
Förderung
- Pudong New Area Science & Technology Development Fund (PKJ2022-Y27)
- Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2022-5)
- National Natural Science Foundation of China (No: 82170225)
Zitieren
APA
You, L. W., Wang, J., Yin, D., Hu, B. J., Cheng, Y., Wang, X. F., Li, H., & Guo, J. (2025). Metabolomics Analysis of Functional Activity Changes in Residual Tumour Cells After IOCS Treatment. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70452
Vancouver
You LW, Wang J, Yin D, Hu BJ, Cheng Y, Wang XF, et al. Metabolomics Analysis of Functional Activity Changes in Residual Tumour Cells After IOCS Treatment. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70452
BibTeX
@article{You2025,
author = {You, Lai-Wei and Wang, Jinhuo and Yin, Dan and Hu, Bao-Ji and Cheng, Yong and Wang, Xue-Fei and Li, Hao and Guo, Jianrong},
title = {Metabolomics Analysis of Functional Activity Changes in Residual Tumour Cells After IOCS Treatment},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70452}
}
EUVIMED